Interim Financial Statements (Tables)

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Reclassifications

The tables below present the impact of the change on the Company’s previously-filed Consolidated Balance Sheet as of December 31, 2019, the Condensed Consolidated Statement of Operations for the three and six months ended June 30, 2019, and the Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2019. The Company’s previously-filed balance sheet has been updated to reflect the addition of the caption Other liabilities for the presentation of up-front and development milestones paid by collaborators that are deferred. There was no impact on the Company’s previously-filed Consolidated Statements of Stockholders’ Equity.

	December 31, 2019
Balance Sheet Data:	As Previously Reported		Adjustments		As Revised
Accrued expenses and other current liabilities	$	1,086.8	$	124.6	$	1,211.4
Deferred revenue - Sanofi (current)	$	395.5	$	(85.0)	$	310.5
Deferred revenue - other (current)	$	196.2	$	(124.6)	$	71.6
Other liabilities - Sanofi (current)	—		$	85.0	$	85.0
Deferred revenue - Sanofi (noncurrent)	$	509.7	$	(482.0)	$	27.7
Deferred revenue - other (noncurrent)	$	109.3	$	(31.7)	$	77.6
Other liabilities - Sanofi (noncurrent)	—		$	482.0	$	482.0
Other noncurrent liabilities	$	286.0	$	31.7	$	317.7

	Three Months Ended June 30, 2019						Six Months Ended June 30, 2019
Statement of Operations Data:	As Previously Reported		Adjustments		As Revised		As Previously Reported		Adjustments		As Revised
Sanofi collaboration revenue	$	349.1	$	(273.3)	$	75.8	$	595.5	$	(537.7)	$	57.8
Bayer collaboration revenue	$	289.0	$	(11.8)	$	277.2	$	565.2	$	(24.0)	$	541.2
Other revenue	$	90.3	$	(70.8)	$	19.5	$	175.1	$	(133.4)	$	41.7
Total revenues	$	1,933.7	$	(355.9)	$	1,577.8	$	3,645.5	$	(695.1)	$	2,950.4
Research and development	$	1,048.3	$	(162.8)	$	885.5	$	1,690.1	$	(318.5)	$	1,371.6
Selling, general, and administrative	$	417.3	$	(122.7)	$	294.6	$	828.1	$	(242.4)	$	585.7
Cost of collaboration and contract manufacturing(1)	$	85.5	$	(6.7)	$	78.8	$	193.8	$	(13.8)	$	180.0
Other operating (income) expense, net	—		$	(63.7)	$	(63.7)	—		$	(120.4)	$	(120.4)
Total operating expenses	$	1,618.1	$	(355.9)	$	1,262.2	$	2,849.9	$	(695.1)	$	2,154.8
(1) In addition to the reclassification of certain amounts in connection with the change in accounting presentation described above, the Company also reclassified certain immaterial reimbursements that were previously classified as collaboration revenue to Cost of collaboration and contract manufacturing.

	Six Months Ended June 30, 2019
Cash Flows Data:	As Previously Reported		Adjustments		As Revised
Cash flows from operating activities:
Increase in deferred revenue	$	401.1	$	(271.3)	$	129.8
Increase in accounts payable, accrued expenses, and other liabilities	$	110.3	$	271.3	$	381.6